<

SANOFI-AVENTIS (EPA:SAN) Press Release: Phase 2 data published in NEJM show potential of frexalimab as high-efficacy therapy in relapsing MS

Transparency directive : regulatory news

15/02/2024 14:00



Other stories

28/04/2024 14:06
28/04/2024 14:10
28/04/2024 12:53
28/04/2024 11:13
28/04/2024 08:19
28/04/2024 13:03
28/04/2024 14:28
28/04/2024 10:48
28/04/2024 09:00
26/04/2024 19:27
28/04/2024 09:23
27/04/2024 23:54
27/04/2024 22:24
28/04/2024 10:15
28/04/2024 11:57
27/04/2024 22:52
27/04/2024 21:00
28/04/2024 14:00
28/04/2024 09:00
28/04/2024 08:49
27/04/2024 19:51
28/04/2024 12:00
28/04/2024 08:53
28/04/2024 01:52
28/04/2024 10:52
28/04/2024 08:15
28/04/2024 14:27
28/04/2024 14:45
28/04/2024 13:17
28/04/2024 12:39
27/04/2024 14:00
28/04/2024 09:42
27/04/2024 20:48
28/04/2024 11:41
27/04/2024 13:26
28/04/2024 03:31
27/04/2024 10:19
28/04/2024 09:00